Samsung Announces FDA-Cleared Irregular Heart Rhythm Notification for Galaxy Watch

 

Samsung Electronics today announced that the Irregular Heart Rhythm Notification (IHRN) feature¹ of the Samsung Health Monitor app² has received FDA clearance. Together with the app’s existing on-demand Electrocardiogram (ECG) function,³ the IHRN feature proactively monitors heart rhythms suggestive of atrial fibrillation (AFib), right from their wrist.

 

“We’re excited to announce that Irregular Heart Rhythm Notification, designed to help millions of people around the world who may not be aware of a potential heart risk, has been cleared by the FDA,” said Hon Pak, Vice President and Head of the Digital Health Team, MX Business at Samsung Electronics. “This is yet another example of how Samsung prioritizes proactive safety solutions and enables users to receive a more holistic understanding of their cardiovascular and overall health.”

 

Cardiovascular disease remains one of the world’s leading causes of death and AFib — a type of arrhythmia — is widely considered a warning sign for major cardiovascular issues that can increase the risk of stroke, heart failure and other cardiovascular complications. Moreover, some of AFib cases are asymptomatic or even silent, leaving people unaware of their risk.

 

That’s why Galaxy Watch offers tools to help users better understand their heart health using the Samsung BioActive Sensor, including on-demand ECG recording and HR Alert function⁴ that detects abnormally high or low heart rates. The addition of the new IHRN feature enables Galaxy Watch users to monitor another aspect of their health.

 

Once activated in the Samsung Health Monitor app, the feature will check for irregular heart rhythms in the background via Galaxy Watch’s BioActive Sensor. If a certain number of consecutive measurements are irregular, Galaxy Watch warns the user of potential AFib activity, prompting them to take an ECG using their watch for a more accurate measurement.

 

The Irregular Heart Rhythm Notification feature will be available as part of the newly announced One UI 5 Watch, coming first to the upcoming Galaxy Watch devices later this year and later expanding to previous editions.

 

¹ The IHRN feature is not intended to provide a notification on every episode of irregular rhythm suggestive of AFib and the absence of a notification is not intended to indicate no disease process is present. It is not intended for users with other known arrhythmias or users under 22 years old.
² Due to market restrictions in obtaining approval/registration as a Software as a Medical Device (SaMD), it only works on watches and smartphones purchased in the markets where service is currently available (however, service may be restricted when users travel to non-service countries).
³ The ECG app is only available in select markets. The ECG app is not intended to replace traditional methods of diagnosis or treatment. The ECG app is not intended for users with known arrhythmias other than AFib or users under 22 years old. Users should not interpret or take clinical action based on the device output without consultation of a qualified healthcare professional.
⁴ The HR Alert function is for general health and wellness purposes and is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease.
⁵ Availability may vary by market, carrier, model or a paired smartphone. Available on Galaxy Watch4 series and later models.